Program areas at MMRF
The immune system is a critical factor in Myeloma prognosis and treatment because it can detect and destroy abnormal cells, including cancer cells. To advance our understanding of how a Myeloma patient's immune system changes during The development of their disease and how it is affected by therapy, we are developing an immune focused database, called The mmrf immune atlas. It utilizes patient samples and clinical data from our groundbreaking commpass study - one of The largest Myeloma datasets in The public domain. The immune atlas is designed to describe The Myeloma patient immune system from disease development, through diagnosis, and The treatment journey. The information, collected from hundreds of patients, will be combined with The existing genomic and clinical data from commpass to develop a more comprehensive picture of Myeloma disease biology. The insights generated through immune atlas will help guide optimal treatment approaches for Myeloma patients in The future.
The Multiple Myeloma Research consortium (mmrc) is a network of leading Myeloma treatment centers that conduct early-stage clinical trials to evaluate novel treatment strategies for patients. This collaborative Research model has conducted close to 100 phase i and phase ii clinical trials, enrolling over a thousand patients to date. The mmrc continues to successfully foster The development of novel therapies and champion rigorous Research and clinical trials. Current mmrc clinical trials that have The potential to make significant contributions for Myeloma treatment include: mydrugthe mmrf mydrug study is The first platform trial in Myeloma. The purpose of mydrug is to test targeted therapies not yet approved in Myeloma, in combination with a standard of care oral triplet therapy, in functionally high-risk Multiple Myeloma patients who demonstrate specific genetic alterations. It is evaluating treatments that are targeted against specific genomic alterations within The Myeloma cells.the scientific hypothesis for The mydrug clinical trial came out of our commpass study, which has generated The largest Myeloma genomics database openly accessible to researchers across The globe. The mydrug study is expected to close new enrollments in 2024. Elo-iber (relapsed/refractory)iberdomide (cc-220) is a new and potentially more potent member of a class of medicines known as immunomodulators (imids), which includes revlimid (lenalidomide) and pomalyst (pomalidomide). This is a phase 1b/2 study that will help determine The optimal dose of iberdomide that can be given to patients - in combination with empliciti (elotuzumab) and dexamethasone - that is safe and has The fewest side effects. Arcellx (relapsed/refractory)cart-ddbcma is a car-t cell therapy candidate that uses patient t cells that have been genetically modified to recognize and kill Myeloma cells. This newer version of car-t cell therapy is designed to form a stronger bond to bcma, a common target for Myeloma treatment, and kill Myeloma cells more efficiently than previous therapies. Beigene (relapsed/refractory)this phase i/ii study is evaluating how safe and effective a new targeted therapy (bgb-11417) is alone, and in combination with kyprolis (carfilzomib) and dexamethasone, in people with relapsed or refractory Myeloma. Bgb-11417 is a bcl-2 inhibitor that is potentially effective in Myeloma patients with The 11;14 chromosomal translocation, which accounts for about 20% of patients. Sarcar ist this trial will determine The side effects and best dose of sarclisa (isatuximab) when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with relapsed/refractory Myeloma. In arm 1, it will determine The maximum tolerated dose (mtd) of sarclisa in combination with standard kyprolis. In arm 2, it will study The safety and efficacy of adding sarclisa doses every other week in combination with weekly kyprolis and dexamethasone. After completion of study treatment, patients are followed up at 30 and 60 days and then every 3 months for up to 3 years.
The mmrf curecloud is a first-of-its-kind registry that collects genomic and clinical information to inform better treatments for patients. The aggregated data is also designed to help researchers discover new targets for Myeloma and form hypotheses for clinical trials.patients participating in curecloud contribute a blood sample that is sent to a central lab for dna sequencing. This sequencing data is combined with The patient's medical records to provide a better understanding of their disease history. All patient data stored in curecloud is then anonymized, aggregated, and will be shared with researchers and medical professionals. To date, more than 1,000 patients have enrolled. In The fall of 2022, two patient reported outcome (pro) surveys were administered to curecloud participants in order to track patient experiences with Myeloma therapy over time and across treatments. The cancer therapy satisfaction questionnaire measured expectations of therapy, feelings about side effects, and satisfaction with cancer therapy. The facit cost survey measured The financial impact related to therapy experienced by Myeloma patients. Curecloud will be closing patient enrollment at The end of 2023.
In addition to The program expenses described above, corresponding activities in alignment with The overall goals of The organization are also supported. These include a portfolio of cutting-edge Research programs in basic science, which identifies new targets through genomics and proteomics Research; validation studies, which identify new compounds and combinations in Research models based on high-priority targets; and innovative clinical trials of novel and combination treatments. As a patient-founded organization, The mmrf stands together with those who are battling Multiple Myeloma - patients, families, physicians, researchers, and investors. At The same time, The mmrf stands apart with its innovative approach. The mmrf generates, interprets, and activates The largest collection of high-quality data and places it in The public domain. The mmrf orchestrates The people, programs, and technologies necessary to speed The discovery of a cure for each and every patient.